Vertex Pharmaceuticals (VRTX) Long-Term Debt Issuances (2009 - 2021)

Vertex Pharmaceuticals' Long-Term Debt Issuances history runs 10 years deep, the most recent figure standing at $10.0 million for Q4 2021.

• In Q4 2021, Long-Term Debt Issuances rose 114.68% year-over-year to $10.0 million; the TTM figure through Sep 2022 stood at $10.0 million (down 42.06% YoY), while the FY2021 annual figure was $22.6 million, up 69.92% from the prior year.
• Long-Term Debt Issuances for Q4 2021 stood at $10.0 million, up from $1.0 million in the prior quarter.
• The five-year high for Long-Term Debt Issuances was $30.0 million in Q4 2017, with the low at $1.0 million in Q3 2021.
• The 5-year median for Long-Term Debt Issuances is $5.3 million (2017), against an average of $7.2 million.
• The sharpest annual moves came in 2017 and 2018: Long-Term Debt Issuances surged 1576.16% in 2017, then plunged 73.78% in 2018.
• Vertex Pharmaceuticals' Long-Term Debt Issuances stood at $30.0 million in 2017, then slumped by 73.78% to $7.9 million in 2018, then grew by 14.52% to $9.0 million in 2019, then tumbled by 48.23% to $4.7 million in 2020, then soared by 114.68% to $10.0 million in 2021.
• Business Quant data shows VRTX's Long-Term Debt Issuances at $10.0 million in Q4 2021, $1.0 million in Q3 2021, and $8.0 million in Q2 2021.